Opus Genetics, Inc. (IRD)

Opus Genetics, Inc., formerly Ocuphire Pharma, is a clinical-stage ophthalmology company based in Durham, North Carolina. It develops treatments for eye diseases, with an emphasis on inherited retinal diseases.

Its gene therapy programs target specific genetic causes of vision loss, including a form of Leber congenital amaurosis caused by mutations in the LCA5 gene and bestrophin-related retinal disease. The company also develops phentolamine ophthalmic solution, an eye drop that reduces pupil size and is being studied in conditions such as reduced low-light vision and age-related near vision loss; a formulation of this drug is approved for reversing pharmacologically induced pupil dilation.

Opus Genetics' common stock trades on the Nasdaq.